30 citations
,
January 2019 in “International Journal of Trichology” Androgenetic alopecia significantly harms quality of life, affecting emotions and relationships.
November 2017 in “British Journal of Dermatology” Organ transplant recipients have a higher risk of skin cancer over time, atopic dermatitis skin shows unusual bacterial and fungal patterns, a new tool for measuring hidradenitis suppurativa severity was created, and gene expression changes in male baldness suggest new treatments.
July 2024 in “Journal of Investigative Dermatology” November 2022 in “American Journal of Clinical Pathology” TURP specimens should be checked for various tumors, not just common prostate issues.
October 2021 in “Revista Medicina Cutánea Ibero-Latino-Americana” PRIDE syndrome helps identify skin side effects from EGFR inhibitors like erlotinib.
December 2021 in “Innovation in aging” Frailer men have a higher risk of worsening prostate problems and serious health events needing hospital care.
9 citations
,
October 1947 in “The Lancet” 1 citations
,
November 1947 in “The Lancet”
3 citations
,
December 2000 in “International Journal of Cosmetic Science” The study created a new method to test drugs that affect hormone processing in skin.
November 1966 in “British Journal of Dermatology” The meeting discussed various skin conditions, treatments, and unusual cases, highlighting the effectiveness of tetracycline in treating rosacea.
52 citations
,
March 2007 in “Dermatologic Therapy” The CLASI is a reliable tool for measuring the severity of cutaneous lupus erythematosus.
September 2021 in “International Journal of Epidemiology” The study concluded that examining the scalp with a special magnifying device helps diagnose the cause of widespread hair loss in adult women.
December 2024 in “Frontiers in Genetics” EGFR and mTOR inhibitors may help manage Olmsted syndrome symptoms.
July 2012 in “European journal of cancer” MPA increases cancer spread by boosting Eph A2 activity.
44 citations
,
September 2015 in “Annals of Oncology” Targeted cancer therapies have a significant but lower risk of causing hair loss compared to chemotherapy.
10 citations
,
January 2011 in “Journal of biomedical optics” OCT is a reliable, noninvasive way to measure hair thickness.
3 citations
,
May 2019 in “Cytotherapy” ATIR101 improves survival in stem cell transplant patients; Australian stem cell treatment decisions are influenced by regulation changes.
8 citations
,
March 2015 in “International Journal of Oncology” Tsc2-deficient stem cells can help understand and treat TSC-related tumors.
1 citations
,
January 2024 in “The Journal of Dermatology” Taxane-based chemotherapy causes more hair loss and skin changes in Asian breast cancer patients.
November 2024 in “Skin Appendage Disorders” Telogen effluvium most affects quality of life in alopecia patients.
Finasteride significantly reduces the risk of prostate cancer.
44 citations
,
November 2016 in “Journal of The American Academy of Dermatology” The updated SALT II tool offers a more precise way to measure scalp hair loss.
29 citations
,
March 2008 in “Dermatologic Surgery” The Cross-section Trichometer is a new tool that can measure hair quantity and detect hair loss and growth.
23 citations
,
January 2008 in “Skin Pharmacology and Physiology” Optical coherent tomography can effectively detect steroid use by analyzing hair changes.
The new testosterone detection kit is accurate, cost-effective, and useful for diagnosing diseases.
1 citations
,
November 2017 in “The journal of investigative dermatology/Journal of investigative dermatology” Mohs micrographic surgery is effective for treating basal cell carcinoma on the eyelid, while radiotherapy has higher recurrence rates, and topical vitamin D3 may reduce and delay BCC formation in mice.
June 2021 in “Dermatologic surgery” Researchers suggest using a standard question and 5-point scale to measure patient satisfaction with acne scar treatments.
9 citations
,
May 2019 in “Experimental Cell Research” HPV genes and estradiol increase a cancer-related signaling pathway, which may be targeted for cervical cancer treatment.
January 2018 in “Journal of the American Academy of Dermatology” More extensive trials are needed to understand tofacitinib's role in treating severe hair loss.